echoloc

Injective Tech Stack

Cosmos-based blockchain optimized for decentralized finance and on-chain markets

Technology, Information and Internet New York 51–200 employees Founded 2018 Nonprofit

Injective is a Cosmos SDK blockchain purpose-built for financial applications, running Tendermint consensus with core infrastructure in Go and Solidity smart contracts. The tech stack reveals a multi-chain integration strategy—Ethereum, Solana, and Binance are all present alongside native Cosmos tooling—suggesting an interoperability play rather than isolation. Active hiring across engineering, marketing, and legal (12 roles posted in the last 30 days) indicates both product expansion and regulatory focus, while the project list shows dual tracks: infrastructure hardening (chain performance, scalability) and user-facing friction reduction (onboarding, acquisition channels).

Tech Stack 26 technologies

Core StackGo Python C++ Rust NetSuite QuickBooks Xero Vue Tailwind CSS JavaScript gRPC Cosmos SDK Tendermint CosmWasm Ethereum Solidity Solana Cosmos Binance Sage Nuxt HTML5 JSON-RPC X Discord Telegram

What Injective Is Building

Challenges

  • Improving chain performance and scalability
  • Streamlining month-end close process
  • Implementing accounting software solutions
  • Expanding user base beyond crypto-native audience
  • Improving onboarding flows
  • Accelerating global market expansion
  • Reducing integration friction
  • Streamlining partner onboarding
  • Evolving regulatory landscape

Active Projects

  • Core components of cosmos-sdk protocol
  • Core components of injective blockchain
  • Open-source golang clients
  • Market-making strategy development
  • Signal-generation pipeline
  • Risk monitoring system
  • Scalable financial reporting solutions
  • Growth experiments across channels
  • Improve onboarding flows
  • Identify new acquisition channels

Hiring Activity

Accelerating15 roles · 10 in 30d

Department

Engineering
4
Marketing
3
Legal
2
Product
2
Research
2
Finance
1

Seniority

Mid
7
Senior
4
Manager
3
Company intelligence

Find more companies like Injective by tech stack, pain points and active projects

Get started free

About Injective

Injective operates a blockchain designed for decentralized finance use cases, enabling on-chain real-world asset markets and trading. The company is structured around protocol development (Cosmos SDK and Injective blockchain core components), market infrastructure (market-making strategies, signal generation, risk monitoring), and user growth (onboarding flows, acquisition experiments). Founded in 2018 and based in New York with 51–200 employees, the organization is navigating both technical scaling challenges (chain performance, integration friction) and business-side expansion (regulatory compliance, non-crypto-native user acquisition, global market reach).

HeadquartersNew York
Company Size51–200 employees
Founded2018
Hiring MarketsUnited States

Frequently Asked Questions

What tech stack does Injective use?

Cosmos SDK, Tendermint, Go, CosmWasm, Solidity, Rust, and Python for core protocol work. Frontend: Vue, Nuxt, Tailwind CSS. Cross-chain integration with Ethereum, Solana, and Binance. Backend services via gRPC and JSON-RPC.

What is Injective working on?

Core infrastructure (Cosmos SDK and blockchain components, Golang clients), financial services (market-making strategies, signal generation, risk monitoring), product improvements (onboarding flows), and growth (acquisition channel experiments and market expansion).

Similar Companies in Technology, Information and Internet

Other companies in the same industry, closest in size

How this profile is built

Injective's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →

This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.